-+ 0.00%
-+ 0.00%
-+ 0.00%

Marker Therapeutics Wins $16.2 Million CPRIT Grant for MT-601 Phase 2 Study

PUBT·11/19/2026 12:06:19
Listen to the news
Marker Therapeutics Wins $16.2 Million CPRIT Grant for MT-601 Phase 2 Study
  • Marker Therapeutics secured a $16.2 million grant from the Cancer Prevention and Research Institute of Texas.
  • The non-dilutive funding will support MT-601’s planned Phase 2 APOLLO study in large B-cell lymphoma patients whose disease relapsed following CAR-T therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-129934), on November 19, 2026, and is solely responsible for the information contained therein.